Sensei Biotherapeutics Inc Cash Flow Conversion Efficiency
Sensei Biotherapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Sensei Biotherapeutics Inc (SNSE) has a cash flow conversion efficiency ratio of -0.056x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.73 Million) by net assets ($191.19 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Sensei Biotherapeutics Inc (2018–2025)
Cash flow conversion efficiency of Sensei Biotherapeutics Inc from 2018 to 2025. This chart illustrates how Sensei Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Sensei Biotherapeutics Inc stock price today for real-time trading data and today's change.
Sensei Biotherapeutics Inc Cash Flow Conversion Ratio Explained
Sensei Biotherapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Sensei Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sensei Biotherapeutics Inc ranked by their cash flow conversion efficiency. Also see Sensei Biotherapeutics Inc market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
eHealth Inc
NASDAQ:EHTH
|
0.057x |
|
Przedsiebiorstwo Przemyslu Spozywczego PEPEES S.A.
WAR:PPS
|
0.120x |
|
Dongkuk Refractories & Steel Co. Ltd
KQ:075970
|
0.000x |
|
SIMPPLE LTD. Ordinary Shares
NASDAQ:SPPL
|
0.712x |
|
AVTECH Sweden AB Series B
ST:AVT-B
|
0.012x |
|
Legend Mining Ltd
AU:LEG
|
-0.023x |
|
SynCore Biotechnology Co Ltd
TWO:4192
|
-0.028x |
|
KLX Energy Services Holdings Inc
NASDAQ:KLXE
|
-0.224x |
Annual Cash Flow Conversion Efficiency for Sensei Biotherapeutics Inc (2018–2025)
The table below shows the annual cash flow conversion efficiency of Sensei Biotherapeutics Inc from 2018 to 2025. Review Sensei Biotherapeutics Inc leverage flexibility ratio to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $18.59 Million | $-20.45 Million | -1.100x | -71.17% |
| 2024-12-31 | $38.39 Million | $-24.67 Million | -0.643x | -30.24% |
| 2023-12-31 | $64.89 Million | $-32.02 Million | -0.493x | -30.75% |
| 2022-12-31 | $103.41 Million | $-39.03 Million | -0.377x | -82.74% |
| 2021-12-31 | $146.51 Million | $-30.26 Million | -0.207x | +81.46% |
| 2020-12-31 | $15.89 Million | $-17.70 Million | -1.114x | -992.43% |
| 2019-12-31 | $-68.66 Million | $-8.57 Million | 0.125x | -35.27% |
| 2018-12-31 | $-53.48 Million | $-10.31 Million | 0.193x | -- |
About Sensei Biotherapeutics Inc
Sensei Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of therapeutics for cancer patients. The company offers PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. It offers Solnerstotug, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune … Read more